Sugi Predict

Sugi Predict / Compounds / SCHEMBL23113643

SCHEMBL23113643

SCHEMBL23113643

CC(C)(C)OC(=O)N1CCN2CCN(c3ncc(C4CCCCC4)s3)C(=O)C2C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP30 Q70CQ3 2/20 0.42
▸ BACE1 P56817 2/20 0.39
▸ CTSD P07339 1/20 0.39
▸ HPGDS O60760 2/20 0.38
▸ JAK2 O60674 1/20 0.37
▸ JAK1 P23458 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ THRB P10828 1/20 0.36
▸ HPGD P15428 1/20 0.35
▸ CHRNA7 P36544 1/20 0.35
▸ ALOX5AP P20292 2/20 0.35
▸ FEN1 P39748 2/20 0.35
▸ DTYMK P23919 1/20 0.35
▸ PDE4B Q07343 1/20 0.35
▸ DDB1 Q16531 1/20 0.35
▸ CRBN Q96SW2 1/20 0.35
▸ OPRM1 P35372 1/20 0.35
▸ OPRD1 P41143 1/20 0.35
▸ OGFRL1 Q5TC84 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23603439 0.86 USP30 (0.40) USP30BACE1CTSDHPGDSJAK2
SCHEMBL23603465 0.83 USP30 (0.52) USP30BACE1CTSDHPGDSJAK2
SCHEMBL23604115 0.77 GPR119 (0.46) USP30HPGDSJAK2JAK1HPGD
SCHEMBL23113653 0.75 USP30 (0.38) USP30CHRNA7
SCHEMBL23113637 0.75 USP30 (0.38) USP30CHRNA7
SCHEMBL23113638 0.75 USP30 (0.38) USP30CHRNA7
SCHEMBL23113756 0.72 CHRNA7 (0.34) CHRNA7
SCHEMBL23604126 0.72 USP30 (0.38) USP30HPGDSKDM4EMAPTTHRB
Trifluoroacetic Acid SCHEMBL23113730 0.72 CHRNA7 (0.34) CHRNA7
SCHEMBL25045196 0.69 TP53 (0.42) USP30KDM4EMAPTTHRBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12049466-B2 Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors FORMA THERAPEUTICS, INC. (US) 2024-07-30 — — US disclosed
EP-3793997-B1 FUSED BICYCLIC COMPOUNDS USEFUL AS UBIQUITIN-SPECIFIC PEPTIDASE 30 INHIBITORS FORMA THERAPEUTICS INC (US) 2024-03-13 — — EP disclosed
US-20210198263-A1 FUSED BICYCLIC COMPOUNDS USEFUL AS UBIQUITIN-SPECIFIC PEPTIDASE 30 INHIBITORS FORMA THERAPEUTICS, INC. (US) 2021-07-01 — — US disclosed
US-20210198263-A1 FUSED BICYCLIC COMPOUNDS USEFUL AS UBIQUITIN-SPECIFIC PEPTIDASE 30 INHIBITORS FORMA THERAPEUTICS, INC. (US) 2021-07-01 — — US disclosed
EP-3793997-A1 FUSED BICYCLIC COMPOUNDS USEFUL AS UBIQUITIN-SPECIFIC PEPTIDASE 30 INHIBITORS Forma Therapeutics, Inc. (US) 2021-03-24 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210198263-A1 FUSED BICYCLIC COMPOUNDS USEFUL AS UBIQUITIN-SPECIFIC PEPTIDASE 30 INHIBITORS USP30, UCHL1, ADRM1 USP30 1/4885BACE1 264/4885CTSD 885/4885
US-12049466-B2 Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors USP30, UCHL1, ADRM1 USP30 1/4885BACE1 264/4885CTSD 885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.